GLPwatch

Involvement of cAMP/EPAC/TRPM2 activation in glucose- and incretin-induced insulin secretion.

Diabetes · 2014

Last updated 2026-05-28

A study found that GLP-1 drugs like exendin-4 and liraglutide, as well as high glucose levels, activate a specific ion channel (TRPM2) in pancreatic cells at very low concentrations. This activation works alongside another process to help trigger insulin release, suggesting a new way that these drugs and glucose work together to control blood sugar.

AI summary of the abstract below.

JournalDiabetes, 2014
Citations59
Relative citation ratio1.91
NIH percentile72
Molecules
Conditions studied Type 2 Diabetes

Abstract

In pancreatic β-cells, closure of the ATP-sensitive K(+) (K(ATP)) channel is an initial process triggering glucose-stimulated insulin secretion. In addition, constitutive opening of background nonselective cation channels (NSCCs) is essentially required to effectively evoke depolarization as a consequence of K(ATP) channel closure. Thus, it is hypothesized that further opening of NSCC facilitates membrane excitability. We identified a class of NSCC that was activated by exendin (ex)-4, GLP-1, and its analog liraglutide at picomolar levels. This NSCC was also activated by increasing the glucose concentration. NSCC activation by glucose and GLP-1 was a consequence of the activated cAMP/EPAC-mediated pathway and was attenuated in TRPM2-deficient mice. The NSCC was not activated by protein kinase A (PKA) activators and was activated by ex-4 in the presence of PKA inhibitors. These results suggest that glucose- and incretin-activated NSCC (TRPM2) works in concert with closure of the KATP channel to effectively induce membrane depolarization to initiate insulin secretion. The current study reveals a new mechanism for regulating electrical excitability in β-cells and for mediating the action of glucose and incretin to evoke insulin secretion, thereby providing an innovative target for the treatment of type 2 diabetes.

Verbatim abstract via PubMed 24824430 ↗